Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 10th 2020

Phase 2 Trial to Study Palbociclib in Early Stage Breast Cancer Based on ctDNA Monitoring

Rose McNulty

Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.

October 4th 2020

Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.

September 30th 2020

Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates

Gianna Melillo

Throughout the United States, counties experiencing persistent poverty have disproportionately higher rates of cancer mortality, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

Maura Abbott, PhD, AOCNP, CPNP, RN, Columbia University School of Nursing

September 29th 2020

Dr Maura Abbott Explains How Vaccine Form Determines Patient Contraindications

Form will determine in which patient populations, and why, a vaccine is not indicated for administration, said Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.

September 28th 2020

Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions

Laura Joszt, MA

Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.

September 23rd 2020

Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020

The uncertainties precipitated by the coronavirus disease 2019 (COVID-19) pandemic around cancer care delivery are a challenging topic to be further addressed at this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

September 23rd 2020

How Oncology Practices Are Identifying, Addressing Health Needs Amid Pandemic

Through risk stratification and identifying social determinants of health, oncology practices are monitoring the direct and indirect effects of the pandemic, noted Jenifer Leaf Jaeger, MD, MPH, senior medical director of HealthEC.

September 22nd 2020

Dr Joseph Alvarnas on Opportunities Presented by Virtual Format of PCOC® 2020

Through this year's virtual format for Patient-Centered Oncology Care® 2020, participants will be able to attend sessions, ask questions, and gain insight in an immediate, efficient way.

September 19th 2020

More Coffee, Longer Survival? Study Highlights Benefit in Metastatic Colon Cancer

Allison Inserro

Patients with advanced colon cancer who drank 4 or more cups of coffee a day had 36% improved survival odds.

September 18th 2020

AACR Report Highlights Disparities in Cancer and the Need for Health Equity

Laura Joszt, MA

Although innovations in cancer treatment have driven down overall cancer death rates and increased the number of survivors living with cancer, that progress has not benefitted everyone with cancer equally.

September 9th 2020

Equity in Care Delivery Still at Top of PCOC 2020 Agenda, Amid “Undue Burden”

Mary Caffrey

Drs Joseph Alvarnas and Kashyap Patel, co-chairs of Patient-Centered Oncology Care® 2020, discuss what attendees can look forward to at the September 25 meeting.

September 7th 2020

Combatting COVID-19 With Real-World Evidence

Jennifer B. Christian, PharmD, MPH, PhD Matthew W. Reynolds, PhD

A vaccine isn’t the panacea many assume it will be. Even when it becomes available, the virus won’t go away. Real world evidence will be needed to guide decision making.

September 5th 2020

Uptake of Palliative Care in Liver Cancer Needs Improvement, Report Says

Allison Inserro

Hepatocellular carcinoma is rising, and so is the need for increased awareness and use of palliative care, say the authors of a recent review.

August 28th 2020

Tafasitamab Plus Lenalidomide Added to NCCN Guidelines

AJMC Staff

NCCN added tafasitamab plus lenalidomide to their oncology practice guidelines for patients with relapsed or refractory DLBCL not otherwise specified.

August 25th 2020

When the Topic Is Dying: A Conversation With Kashyap Patel, MD

Mary Caffrey

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, associate editor of Evidence-Based Oncology, and vice president of the Community Oncology Alliance, discusses his new book.

August 24th 2020

Psychosocial Support for Patients With Cancer Waning as COVID-19 Pandemic Continues

Jaime Rosenberg

A recent survey showed the disruption in cancer care as a result of the pandemic is worrying professionals who provide psychosocial support to patients.

August 16th 2020

Sidebar: CMS Seeks to Fix Medicaid Best-Price Barriers in Value-Based Contracting for High-Cost Therapies in Medicaid

Mary Caffrey

Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.

August 13th 2020

Amid Effort to Shrink Cancer Disparities, Authors Say COVID-19 Will Widen Them

Mary Caffrey

As the American Society of Clinical Oncology calls for more aggressive efforts to bring equity to cancer care, authors in JAMA Oncology say COVID-19 is creating wider gaps.

August 2nd 2020

Tafasitamab Combination Approved for Adults With R/R DLBCL

Mary Caffrey

A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.

July 21st 2020

American Oncology Network, LLC Announces New Advisory Board Chair and Executive Committee

The American Oncology Network, LLC, has added 5 medical oncologists to its Executive Committee.

July 20th 2020

Access to Care: Burris Says United With Our Patients, We Accelerate Progress Together

Maggie L. Shaw

“We’ve had advancements, but we need to go faster,” said ASCO President Howard A. "Skip" Burris III, MD, as he stressed the importance of advancing therapies for better patient outcomes by addressing obstacles to patients’ care. “Access to care, access to clinical trials, and access to information are really key.”

July 14th 2020

Florida Cancer Specialists Names New CEO

Nathan H. Walcker will succeed Brad Prechtl on August 1, 2020.

July 1st 2020

Don't Delay Cancer Care During COVID-19 Crisis

Amy McNally, MD

Federal and state officials have implemented policies and safeguards to slow transmission of the virus. Most troubling were state moratoriums on “elective” surgical procedures.

June 19th 2020

From the Editor-in-Chief: Bigger Questions of Systems, Viruses, and the Lives of Real People

Joseph Alvarnas, MD

As I recall the early days of the HIV/AIDS pandemic, what stands out most is its profound human cost and the courage of those who helped our society transcend it. We are in the midst of a time in which the human toll of COVID-19 and the enormity of the path ahead are clear.

June 17th 2020

Conference Coverage: Community Oncology Alliance

Maggie L. Shaw Mary Caffrey

Coverage from the Community Oncology Alliance Virtual Meeting, held April 23-24, 2020.

June 17th 2020

How to Optimize Cancer Therapy When Coronavirus Hits the Fan

Afsaneh Barzi, MD, PhD Sarmad Sadeghi, MD, PhD

The American Society of Clinical Oncology recommends that cancer survivors who have completed their treatment and are under surveillance with no known evidence of disease are to be kept out of care facilities to avoid developing COVID-19.

June 16th 2020

FDA Grants Accelerated Approval to Lurbinectedin in Metastatic Small Cell Lung Cancer

AJMC Staff

Investigators reported in Lancet Oncology that second-line treatments are needed in small cell lung cancer, as few options exist for these patients once first-line therapy fails.

June 11th 2020

Claims Identification of Patients With Severe Cancer-Related Symptoms

Richard W. DeClue, PhD, MPH Dana Drzayich Antol, MS Adrianne W. Casebeer, PhD, MS, MPP Todd Michael, PharmD, RPh Marina Sehman, PharmD Andrew Renda, MD, MPH Sarika Ogale, PhD Stephen Stemkowski, PhD, MHA Bryan Loy, MD

The authors established a claims-based mechanism for identifying patients with lung cancer with more severe patient-reported cancer-related symptoms who could benefit from engagement with health care programs.

June 11th 2020

Aaron Lyss on What the Next Oncology Payment Model Should Include

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

June 6th 2020

Aaron Lyss Outlines Lessons Learned From Data Analytics

In each performance period of the Oncology Care Model for which we've received data, we've seen different aspects of care that we can improve upon in the following 6 months, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

...

18 19 20 21 22 23 24 25 26

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions